MTOR and hepatocellular carcinoma: It is quite a coincidence that circRPN2 could bind to ENO1 and accelerates its degradation to promote glycolytic reprogramming through the AKT/mTOR pathway, thereby inhibiting hepatocellular carcinoma (HCC) proliferation and metastasis (Li et al., 2022).